Company intelligence / Profile preview

Simcha

New Haven, Connecticut, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Simcha Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation cytokine immunotherapies for cancer. The company's proprietary platform uses directed evolution to engineer cytokines that overcome natural biological limitations, such as endogenous inhibitors. Its lead candidate, ST-067, is a decoy-resistant Interleukin-18 (IL-18) designed to maintain potent anti-tumor activity by evading the IL-18 binding protein (IL-18BP). Simcha is currently advancing ST-067 through Phase 1/2 clinical trials as both a monotherapy and in combination with other agents for advanced solid tumors. The company was founded on groundbreaking research from Yale University and is backed by prominent life science investors.

Therapeutic areas: Oncology
Modalities: CytokineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Simcha.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcha.

Explore the full profile